Cargando…

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era

SIMPLE SUMMARY: The modern treatment of chronic lymphocytic leukemia (CLL) has dramatically changed thanks to the development of effective mechanism-based drugs, which have proven to be superior to chemoimmunotherapy in all age groups. Because the choice of treatment for older patients largely depen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urso, Antonio, Cavazzini, Francesco, Ballardini, Maria Pia, Gambara, Silvia, Consolo, Sara, Rigolin, Gian Matteo, Cuneo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417156/ https://www.ncbi.nlm.nih.gov/pubmed/37568676 http://dx.doi.org/10.3390/cancers15153859

Ejemplares similares

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
por: Rigolin, Gian Matteo, et al.
Publicado: (2023)

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
por: Sessa, Mariarosaria, et al.
Publicado: (2020)

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
por: Cuneo, Antonio, et al.
Publicado: (2014)

Genetic subclonal complexity and miR125a-5p down-regulatio identify a subset of patients with inferior outcome in low-ris CLL patients
por: Rigolin, Gian Matteo, et al.
Publicado: (2013)

Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report
por: Panareo, Stefano, et al.
Publicado: (2020)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
por: Cuneo, Antonio, et al.
Publicado: (2020)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
por: Rigolin, Gian Matteo, et al.
Publicado: (2017)

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia
por: Cavallari, Maurizio, et al.
Publicado: (2018)

Emerging Therapies in CLL in the Era of Precision Medicine
por: Iyer, Prajish, et al.
Publicado: (2023)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
por: Marchetti, Monia, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death
por: Salaro, Erica, et al.
Publicado: (2016)

Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in Splenic Marginal Zone Lymphoma
por: Bardi, Antonella, et al.
Publicado: (2011)

Umbelliprenin Induces Apoptosis in CLL Cell Lines
por: Ziai, Seyed Ali, et al.
Publicado: (2012)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
por: Edelmann, Jennifer, et al.
Publicado: (2023)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway
por: Agnoletto, Chiara, et al.
Publicado: (2014)

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
por: Scarfò, Lydia, et al.
Publicado: (2020)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Resist-Free Directed Self-Assembly Chemo-Epitaxy Approach for Line/Space Patterning
por: Giammaria, Tommaso Jacopo, et al.
Publicado: (2020)

Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy
por: Martinelli, Sara, et al.
Publicado: (2016)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2023)

Delirium in acute promyelocytic leukemia patients: two case reports
por: Rigolin, Gian Matteo, et al.
Publicado: (2013)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
por: Rawstron, Andy C., et al.
Publicado: (2018)

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
por: Visentin, Andrea, et al.
Publicado: (2019)

Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine
por: Fahrmann, Johannes F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hahuid1e0h3ottlon48g35r203